| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/17/2004 | US20040116354 Supplementary immunotherapeutics to be used after lung cancer removal |
| 06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 06/17/2004 | US20040116352 Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 |
| 06/17/2004 | US20040116351 Administering to a patient an opiate destruction-inhibitor |
| 06/17/2004 | US20040116350 Contacting the cell with an antioxidant, wherein the antioxidant is effective in reducing antibody mediated generation of superoxide or hydrogen peroxide in the cell |
| 06/17/2004 | US20040116346 For use in therapy of anemia, as well as in other functions associated with assays for EPO-R, studying EPO and EPO-R function, purification of EPO-R |
| 06/17/2004 | US20040116339 Compounds that bind P2Y2 or P2Y1 receptors |
| 06/17/2004 | US20040116330 Preventive/therapeutic method for cancer |
| 06/17/2004 | US20040116329 Administering to at least one cell in a blood vessel wall after an angioplastic procedure an amount of a compound capable of inhibiting the ubiquitin-proteasome protein degradation pathway in cell effective to prevent proliferation of cell |
| 06/17/2004 | US20040116328 Condensed imidazole derivatives |
| 06/17/2004 | US20040116327 Administering compound capable of simultaneously binding PPAR alpha and PPAR gamma or concomitantly administering a compound that selectively binds PPAR alpha with a compound that selectively binds PPAR gamma to prevent rupture |
| 06/17/2004 | US20040115837 Characterizing in vitro transfer of drug from non-aqueous liquid composition to aqueous medium; monitoring drug diffusion from sustained release dosage |
| 06/17/2004 | US20040115810 Stem cell differentiation-inducing promoter |
| 06/17/2004 | US20040115773 Serpin in bifidobacteria |
| 06/17/2004 | US20040115762 Comprises nucleotide sequences coding enzymatic polypeptide associated biosynthesis of nystatin and treatment of bacterial, fungal and parasitic infections; immunosuppressant; antitumor agents |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115732 Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof |
| 06/17/2004 | US20040115690 Method of detecting inflammatory lung disorders |
| 06/17/2004 | US20040115656 Androgen receptor down-regulatory-associated proteins(ARDAPs) for use in reduction of transactivation activity of androgen receptors and treatment of tumors; gene expression inhibition and anticarcinogenic agents |
| 06/17/2004 | US20040115636 Modulation of interleukin 18 expression |
| 06/17/2004 | US20040115587 Methods and systems for enabling and stabilizing tooth movement |
| 06/17/2004 | US20040115483 Crystal modification of a cyclic depsipeptide having improved strength |
| 06/17/2004 | US20040115433 Mixture of hydrophobic polymer core and nanoparticles; immobilization |
| 06/17/2004 | US20040115331 Suitable for inclusion in food |
| 06/17/2004 | US20040115309 Food supplement |
| 06/17/2004 | US20040115305 Charging gum base components and all of the chewing gum additives into a mixing apparatus; operating the apparatus at atmospheric pressure to obtain the chewing gum, subject to the limitation that the gum base does not contain a vinyl polyester |
| 06/17/2004 | US20040115290 Modulation of inflammation by hops fractions and derivatives |
| 06/17/2004 | US20040115289 Using as active principle, at least one sesquiterpene lactone or one analogue of the sesquiterpene lactones in the manufacture of a medicament or of a cosmetic composition intended to treat alopecia, to stimulate hair growth |
| 06/17/2004 | US20040115285 Orally administering a proanthocyanidins containing plant extract to hyperglycemic patient to lower elevated level of blood glucose or glycosylated hemoglobin levels |
| 06/17/2004 | US20040115284 Use of gamma-GT inhibitors for the treatment of degenerative diseases |
| 06/17/2004 | US20040115283 Administering parenterally a therapeutically effective amount of one or more arsenic compounds |
| 06/17/2004 | US20040115282 May be administered for preparing the colon for surgical or diagnostic procedures or childbirth |
| 06/17/2004 | US20040115272 Stability and dissolvability; for the therapy of an infectious disease |
| 06/17/2004 | US20040115271 Hydration compositions for corneal pre-surgery treatment |
| 06/17/2004 | US20040115267 Both active substances are contained in the same administration unit as two separately formulated subunits |
| 06/17/2004 | US20040115266 Oral itraconazole formulations and methods of making the same |
| 06/17/2004 | US20040115265 Minimal physical and chemical incompatibility (including minimal pravastatin:aspirin interaction), and reduced side effects normally associated with use of such drugs |
| 06/17/2004 | US20040115264 Bioavailability |
| 06/17/2004 | US20040115263 Administering therapeutically effective amount of bupropion or pharmaceutically acceptable salts thereof |
| 06/17/2004 | US20040115262 Formulations and dosage forms for controlled delivery of topiramate |
| 06/17/2004 | US20040115261 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 06/17/2004 | US20040115260 cefquinome and a prolonged release vehicle characterised in that the prolonged release vehicle comprises a mixture of an oil and aluminium distearate |
| 06/17/2004 | US20040115259 a floating tablet including as active principle alfuzosin |
| 06/17/2004 | US20040115257 Retinoid agent capsule system |
| 06/17/2004 | US20040115255 Method and composition for solubilising a biologically active compound with low water solubility |
| 06/17/2004 | US20040115244 Methods and compositions for nicotine replacement therapy |
| 06/17/2004 | US20040115243 Compositions for oral delivery of nutrients and pharmaceuticals |
| 06/17/2004 | US20040115237 vascular graft comprising a composite comprising a polymer and an active ingredient such a aspirin, incorporated into composite with ultrasonication |
| 06/17/2004 | US20040115236 implantable sustained-release dosage form comprising a drug delivery device and an inhibitor of mast cell-mediated inflammation such as chromene |
| 06/17/2004 | US20040115233 Composition for improving skin environment and clothes thereof |
| 06/17/2004 | US20040115227 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 06/17/2004 | US20040115213 Use of IL-2 receptor antibodies |
| 06/17/2004 | US20040115199 Method for down-regulating osteoprotegerin ligand activity |
| 06/17/2004 | US20040115185 Placental alkaline phosphatase to control diabetes |
| 06/17/2004 | US20040115181 Composition for transmucosal adminstration containing conenzyme q as the active ingredient |
| 06/17/2004 | US20040115175 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 06/17/2004 | US20040115164 Soft filament occlusive device delivery system |
| 06/17/2004 | US20040115162 Dermatological preparations |
| 06/17/2004 | US20040115160 e.g., N-capryloyloxypropyl-N,N,N-trimethylammonium iodide; for disinfecting and preserving contact lenses |
| 06/17/2004 | US20040115150 moisturizer(s), antioxidant(s) or mineral salt(s) . |
| 06/17/2004 | US20040115141 phospholipid complexes of flavanolignanes extracted from Silybum marianum; phospholipid complexes of Vitis vinifera standardized extract and phospholipid complexes of triterpenes extracted from Glycyrrhiza glabra |
| 06/17/2004 | US20040115136 L-tartrate derivative; stable particle size distribution; reproducible dosing; can be stored under varying temperature and humidity conditions |
| 06/17/2004 | US20040115133 High bioavailability pain relief; masking agent for easier delivery; nose spray |
| 06/17/2004 | US20040115132 Having chemical switch triggering release in target site of soluble active material; controlling size and contents; high loading capacity; facilitating aggregation and crystallization |
| 06/17/2004 | US20040115127 Simultaneous selective binding and activating |
| 06/17/2004 | US20040112719 Extendable belt conveyor |
| 06/17/2004 | DE20220901U1 Film coating composition for controlled release of active ingredient e.g. metoprolol, comprises an acrylic polymer dispersion, a surfactant, sodium stearyl fumarate and a water-containing liquid |
| 06/17/2004 | DE10256080A1 Tiotropiumhaltige Arzneimittelkombination für die Inhalation Tiotropiumhaltige drug combination for inhalation |
| 06/17/2004 | DE10255861A1 Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase |
| 06/17/2004 | DE10254995A1 Verfahren zur enzymatischen Reduktion von NAD und NADP Process for the enzymatic reduction of NAD and NADP |
| 06/17/2004 | CA2791165A1 A conjugate comprising cholesterol linked to tetracycline |
| 06/17/2004 | CA2509955A1 Formulations useful against hepatitis c virus infections |
| 06/17/2004 | CA2508783A1 S-substituted n-1-¬(hetero) aryl|alkyl-n'-¬(hetero)aryl|alkylisothiocarbamides, a method for the preparation of these, physiologically active s-substituted n-1-¬(hetero)aryl|alkyl-n'-¬(hetero)aryl|alkylisothiocarbamides, a pharmaceutical composition and method of treatment |
| 06/17/2004 | CA2508581A1 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/17/2004 | CA2508546A1 Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
| 06/17/2004 | CA2508542A1 Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
| 06/17/2004 | CA2508536A1 An exopolysaccharides delivery system for active molecules |
| 06/17/2004 | CA2508487A1 Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 06/17/2004 | CA2508479A1 Compounds resistant to metabolic deactivation and methods of use |
| 06/17/2004 | CA2508319A1 Jnk inhibitors |
| 06/17/2004 | CA2508315A1 Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders |
| 06/17/2004 | CA2508311A1 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |
| 06/17/2004 | CA2508309A1 Remedy |
| 06/17/2004 | CA2508301A1 Low viscosity liquid dosage forms |
| 06/17/2004 | CA2507851A1 Combination of ibuprofen and oxycodone for acute pain relief |
| 06/17/2004 | CA2507848A1 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 06/17/2004 | CA2507815A1 High enantiomeric purity dexanabinol for pharmaceutical compositions |
| 06/17/2004 | CA2507780A1 Indol derivatives and their use as kinase inhibitors |
| 06/17/2004 | CA2507762A1 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| 06/17/2004 | CA2507750A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | CA2507748A1 Pharmaceutical formulations comprising .beta.-2 adrenoreceptor agonists and xanthines |
| 06/17/2004 | CA2507704A1 Flavanols and procyanidins promote homeostasis |
| 06/17/2004 | CA2507665A1 Preventive or remedy for diseases caused by hyperglycemia |
| 06/17/2004 | CA2507641A1 Method of producing macrolide compound |
| 06/17/2004 | CA2507609A1 Method and compositions for treating anxiety |
| 06/17/2004 | CA2507450A1 Use of a histone deacetylase inhibitor for treating muscular dystrophies |
| 06/17/2004 | CA2507334A1 Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
| 06/17/2004 | CA2507244A1 Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
| 06/17/2004 | CA2507230A1 Tough polymers |
| 06/17/2004 | CA2507036A1 Materials and methods for treating ocular-related disorders |